Oncology
Myeloma Patients May Not Need Treatment Forever
The ENDURANCE trial found no overall survival benefit from indefinite lenalidomide maintenance compared with stopping after two years in standard-risk, newly diagnosed multiple myeloma patients who did not undergo transplant. This is a de-escalation story with real cost and quality-of-life consequences.
Metastatic Cancer Means Living With Loss Before the End
Surviving Cancer Is Not the Same as Being Recovered
MRD Testing Moves From Prognosis Toward Treatment Action
Colon Cancer Immunotherapy Moves Into the Adjuvant Access Test
Cancer Is Chaos. Patients Should Not Have to Become Their Own Operating System
India’s emergency price-cap rise for cisplatin and carboplatin exposes a blunt oncology truth
G7 Cancer Call and WHA Precision Medicine Resolution: A Moment to Turn Ambition Into Delivery
CAR-T Starts Moving From Factory Medicine to In-Patient Engineering
AML’s Frontline Future Starts With Finding the Mutation Fast
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.